"ERCC2 Somatic Mutations as Biomarkers of Platinum Chemotherapy Sensitivity in Urothelial Carcinoma and other Platinum-treated Tumors"
Co-Principal Investigators:
- Hikmat A. Al-Ahmadie, MD, Memorial Sloan-Kettering Cancer Center
- Michael F. Berger, PhD, Memorial Sloan-Kettering Cancer Center
- Levi Garraway, MD, PhD, The Broad Institute of MT and Harvard
- Gopa Iyer, MD, Memorial Sloan-Kettering Cancer Center
- Oscar Lin, MD, PhD, Memorial Sloan-Kettering Cancer Center
- Irina Ostrovnaya, PhD, Memorial Sloan-Kettering Cancer Center
- David B. Solit, MD, Memorial Sloan-Kettering Cancer Center
- Eliezer Van Allen, MD, The Broad Institute of MT and Harvard
Abstract
